New immunotherapy cocktail shows promise for Hard-to-Treat cancers

This early-phase study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, measure drug levels in the body, and get an early look at whether the combination can shrink tumors. Because these drugs work by boosting the immune system rather than curing the cancer outright, and ongoing treatment is typically needed, this is classified as disease control.